No Data
No Data
Nanobiotix: Innovating Treatments and Transparency
ADRs End Higher; Nanobiotix S.A. Climbs 12%
Stifel Initiates Nanobiotix With Buy Rating
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Nanobiotix Announced New Data At ASCO 2924, Showing 48% ORR In Evaluable Anti-PD-1 Naïve Patients (N=25); 28% ORR In Evaluable Anti-PD-1 Resistant Patients (N=25) As Per RECIST 1.1
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By Anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior Anti-PD-1 Therapy
No Data